Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS Registry)

Peter R. Kowey, James A. Reiffel, Robert Myerburg, Gerald V. Naccarelli, Douglas L Packer, Craig M. Pratt, Michael J. Reiter, Albert L. Waldo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Among patients with atrial fibrillation (AF), the risk of thromboembolism is a significant concern. However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low. In the present study, we have provided information on anticoagulation use reported during the recent Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry. Among patients identified by their physician at baseline to be at an increased risk of stroke, as determined from an assessment of the medical history, 74% received warfarin and 29% received aspirin. Post hoc analysis of warfarin use stratified by Congestive heart failure, Hypertension, Age, Diabetes, Stroke, (CHADS2) doubled score revealed that at the end of the study, warfarin use was 73% (155 of 213) and 66% (185 of 280) in the rate- and rhythm-control patients with a score of ≥2, respectively, compared to 60% (183 of 306) and 49% (322 of 662) in the rate- and rhythm-control patients with a score of <2, respectively. The practicing cardiologists who participated in this registry initiated anticoagulation therapy in most of their patients with AF. However, warfarin use is not yet in line with the guidelines and evidence-based recommendations. Patients considered at no risk of stroke appear to have been overprescribed anticoagulant agents, and a considerable portion of high-risk patients did not receive warfarin. In conclusion, these results suggest that continued physician education of appropriate anticoagulation use in patients with AF is needed.

Original languageEnglish (US)
Pages (from-to)1130-1134
Number of pages5
JournalAmerican Journal of Cardiology
Volume105
Issue number8
DOIs
StatePublished - Apr 15 2010

Fingerprint

Warfarin
Atrial Fibrillation
Aspirin
Registries
Stroke
Therapeutics
Physicians
Cardiologists
Thromboembolism
Anticoagulants
Heart Failure
Guidelines
Hypertension
Education

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS Registry). / Kowey, Peter R.; Reiffel, James A.; Myerburg, Robert; Naccarelli, Gerald V.; Packer, Douglas L; Pratt, Craig M.; Reiter, Michael J.; Waldo, Albert L.

In: American Journal of Cardiology, Vol. 105, No. 8, 15.04.2010, p. 1130-1134.

Research output: Contribution to journalArticle

Kowey, PR, Reiffel, JA, Myerburg, R, Naccarelli, GV, Packer, DL, Pratt, CM, Reiter, MJ & Waldo, AL 2010, 'Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS Registry)', American Journal of Cardiology, vol. 105, no. 8, pp. 1130-1134. https://doi.org/10.1016/j.amjcard.2009.11.047
Kowey, Peter R. ; Reiffel, James A. ; Myerburg, Robert ; Naccarelli, Gerald V. ; Packer, Douglas L ; Pratt, Craig M. ; Reiter, Michael J. ; Waldo, Albert L. / Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS Registry). In: American Journal of Cardiology. 2010 ; Vol. 105, No. 8. pp. 1130-1134.
@article{d6420257cb4f47b7b6c820f5729f5da2,
title = "Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS Registry)",
abstract = "Among patients with atrial fibrillation (AF), the risk of thromboembolism is a significant concern. However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low. In the present study, we have provided information on anticoagulation use reported during the recent Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry. Among patients identified by their physician at baseline to be at an increased risk of stroke, as determined from an assessment of the medical history, 74{\%} received warfarin and 29{\%} received aspirin. Post hoc analysis of warfarin use stratified by Congestive heart failure, Hypertension, Age, Diabetes, Stroke, (CHADS2) doubled score revealed that at the end of the study, warfarin use was 73{\%} (155 of 213) and 66{\%} (185 of 280) in the rate- and rhythm-control patients with a score of ≥2, respectively, compared to 60{\%} (183 of 306) and 49{\%} (322 of 662) in the rate- and rhythm-control patients with a score of <2, respectively. The practicing cardiologists who participated in this registry initiated anticoagulation therapy in most of their patients with AF. However, warfarin use is not yet in line with the guidelines and evidence-based recommendations. Patients considered at no risk of stroke appear to have been overprescribed anticoagulant agents, and a considerable portion of high-risk patients did not receive warfarin. In conclusion, these results suggest that continued physician education of appropriate anticoagulation use in patients with AF is needed.",
author = "Kowey, {Peter R.} and Reiffel, {James A.} and Robert Myerburg and Naccarelli, {Gerald V.} and Packer, {Douglas L} and Pratt, {Craig M.} and Reiter, {Michael J.} and Waldo, {Albert L.}",
year = "2010",
month = "4",
day = "15",
doi = "10.1016/j.amjcard.2009.11.047",
language = "English (US)",
volume = "105",
pages = "1130--1134",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS Registry)

AU - Kowey, Peter R.

AU - Reiffel, James A.

AU - Myerburg, Robert

AU - Naccarelli, Gerald V.

AU - Packer, Douglas L

AU - Pratt, Craig M.

AU - Reiter, Michael J.

AU - Waldo, Albert L.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Among patients with atrial fibrillation (AF), the risk of thromboembolism is a significant concern. However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low. In the present study, we have provided information on anticoagulation use reported during the recent Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry. Among patients identified by their physician at baseline to be at an increased risk of stroke, as determined from an assessment of the medical history, 74% received warfarin and 29% received aspirin. Post hoc analysis of warfarin use stratified by Congestive heart failure, Hypertension, Age, Diabetes, Stroke, (CHADS2) doubled score revealed that at the end of the study, warfarin use was 73% (155 of 213) and 66% (185 of 280) in the rate- and rhythm-control patients with a score of ≥2, respectively, compared to 60% (183 of 306) and 49% (322 of 662) in the rate- and rhythm-control patients with a score of <2, respectively. The practicing cardiologists who participated in this registry initiated anticoagulation therapy in most of their patients with AF. However, warfarin use is not yet in line with the guidelines and evidence-based recommendations. Patients considered at no risk of stroke appear to have been overprescribed anticoagulant agents, and a considerable portion of high-risk patients did not receive warfarin. In conclusion, these results suggest that continued physician education of appropriate anticoagulation use in patients with AF is needed.

AB - Among patients with atrial fibrillation (AF), the risk of thromboembolism is a significant concern. However, the reported use of warfarin among patients with AF at elevated risk of stroke remains low. In the present study, we have provided information on anticoagulation use reported during the recent Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry. Among patients identified by their physician at baseline to be at an increased risk of stroke, as determined from an assessment of the medical history, 74% received warfarin and 29% received aspirin. Post hoc analysis of warfarin use stratified by Congestive heart failure, Hypertension, Age, Diabetes, Stroke, (CHADS2) doubled score revealed that at the end of the study, warfarin use was 73% (155 of 213) and 66% (185 of 280) in the rate- and rhythm-control patients with a score of ≥2, respectively, compared to 60% (183 of 306) and 49% (322 of 662) in the rate- and rhythm-control patients with a score of <2, respectively. The practicing cardiologists who participated in this registry initiated anticoagulation therapy in most of their patients with AF. However, warfarin use is not yet in line with the guidelines and evidence-based recommendations. Patients considered at no risk of stroke appear to have been overprescribed anticoagulant agents, and a considerable portion of high-risk patients did not receive warfarin. In conclusion, these results suggest that continued physician education of appropriate anticoagulation use in patients with AF is needed.

UR - http://www.scopus.com/inward/record.url?scp=77950457719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950457719&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.11.047

DO - 10.1016/j.amjcard.2009.11.047

M3 - Article

C2 - 20381665

AN - SCOPUS:77950457719

VL - 105

SP - 1130

EP - 1134

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -